Results 61 to 70 of about 552 (131)

Predictors of post-COVID syndrome: opposing effects of arterial stiffness and targeted therapy in acute COVID-19

Рациональная фармакотерапия в кардиологии
Aim. To evaluate the impact of arterial stiffness and targeted therapy (biologic drugs and Janus kinase inhibitor) during the acute phase of coronavirus disease 2019 (COVID-19) on the risk of post-COVID syndrome (PCS).
V. I. Podzolkov, Ilya I. Shvedov, Nino A. Dzhaiani, Anna E. Bragina   +3 more
doaj   +1 more source

Effectiveness and safety of olokizumab and levilimab in patients with COVID-19 in 2022: a cohort study

Journal of Volgograd State Medical University
A single-center observational cohort study of the use of levilimab and olokizumab in patients with COVID-19 was conducted. Purpose was to evaluate the effectiveness and safety of olokizumab and levilimab in the infectious diseases hospital of the Volgograd region in 2022.
Vladimir I. Petrov, Anastasia Yu. Ryazanova, Natalya S. Tokareva   +2 more
openaire   +1 more source

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis

Drug Design, Development and Therapy, 2017
Maria Gabriella Raimondo,1 Martina Biggioggero,1 Chiara Crotti,1 Andrea Becciolini,2 Ennio Giulio Favalli2 1Department of Clinical Sciences and Health Community, Division of Rheumatology, University of Milan, 2Department of Rheumatology, Gaetano Pini ...
Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG   +4 more
doaj  

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. [PDF]

Ann Rheum Dis, 2022
Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, Samsonov M, Smolen JS, Fleischmann RM.   +8 more
europepmc   +1 more source

Neutralizing Antibodies in COVID-19 Serum from Tatarstan, Russia. [PDF]

Int J Mol Sci, 2023
Hamza S, Martynova E, Garanina E, Shakirova V, Bilalova A, Moiseeva S, Khaertynova I, Ohlopkova O, Blatt N, Markelova M, Khaiboullina S.   +10 more
europepmc   +1 more source

Olokizumab reduces the risks of death in hospitalized patients with moderate and severe COVID-19

Infectious diseases: News, Opinions, Training, 2022
E.V. Tavlueva, A.E. Markarov, M.A. Petrushin, A.A. Vizel, G.L. Ignatova, V.N. Antonov, A.S. Agaf'ina, B.A. Bakirov, V.M. Mozgovaya, O.V. Filon, A.V. Zinkovskaya, A.N. Dolgorukova, M.Yu. Samsonov   +12 more
openaire   +1 more source

Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies

European Journal of Rheumatology, 2021
Mark C. Genovese, Patrick Durez, Roy Fleischmann, Yoshiya Tanaka, Daniel Furst, Hisashi Yamanaka , Elena Korneva, Igor Vasyutin, Tsutomu Takeuchi   +8 more
doaj   +1 more source

Interleukin-6 in Natural and Pathophysiological Kidney Aging. [PDF]

Cells
Mutig K, Singh PB, Lebedeva S.
europepmc   +1 more source

IL-6 Signaling in Immunopathology: From Basic Biology to Selective Therapeutic Intervention. [PDF]

Immunotargets Ther
Schumertl T, Lokau J, Garbers C.
europepmc   +1 more source

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. [PDF]

Ann Rheum Dis, 2022
Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, Maslyanskiy AL, Samsonov M, Stoilov R, Zonova EV, Genovese M.   +10 more
europepmc   +1 more source